A Randomized Phase II, Placebo-controlled, Multicenter Study Evaluating Efficacy and Safety of Regorafenib in Patients With Metastatic Bone Sarcomas
Phase of Trial: Phase II
Latest Information Update: 29 Jun 2016
At a glance
- Drugs Regorafenib (Primary)
- Indications Chondrosarcoma; Ewing's sarcoma; Osteosarcoma
- Focus Therapeutic Use
- Acronyms REGOBONE
- 21 Jun 2016 Planned number of patients changed from 108 to 132.
- 21 Jun 2016 Planned End Date changed from 1 Mar 2019 to 1 Mar 2020.
- 21 Jun 2016 Planned primary completion date changed from 1 Sep 2016 to 1 Sep 2019.